IOS-1002, a trispecific mAb targeting LILRB1, LILRB2, and KIR3DL1, blocks HLA-G/ANGPTL engagement to inhibit ITIM signaling and polarize macrophages toward immunostimulatory phenotype, enhancing tumor phagocytosis (Figure 5) 368. Here, HLA-G is linked to neoplasm.